A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme

PHASE3RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

November 8, 2015

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2025

Conditions
Anaplastic OligoastrocytomaGlioblastoma
Interventions
DRUG

Temozolomide

Two weeks after surgery, temozolomide was administered orally at 200 mg·m-2 ·d -1 for 5 days. From day 29, patients were treated with a standard therapy regimen (Stupp).

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER